Characterizing Plasma Biomarkers of Cerebral Amyloid Angiopathy
Date
2024-07-26
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
BACKGROUND: Cerebral Amyloid Angiopathy (CAA) is characterized by the progressive deposition of beta-amyloid in cortical and leptomeningeal small vessels leading to hemorrhagic stroke and dementia. While CAA is diagnosed using Boston Criteria 2.0, they are not always possible to apply. Plasma biomarkers (Aβ42, Aβ40, phosphorylated-tau (p-tau), neurofilament light chain (NfL) and Glial Fibrillary Acidic Protein (GFAP)) might improve diagnostic accuracy. This study evaluates whether plasma biomarkers: (i) differ in CAA compared to controls (ii) discriminate a diagnosis of CAA individually and in combination and (iii) are associated with cognition and neuroimaging biomarkers. METHODS: Data are from a multi-centre cohort study of participants with probable CAA and healthy controls. Participants had plasma collected and underwent neurocognitive evaluation and magnetic resonance imaging. Aβ was quantified with two independent methods: immunoprecipitation mass-spectrometry (IPMS) and single molecule array assay (Simoa). Plasma p-tau181, NfL and GFAP were quantified with Simoa. Neuroimaging biomarkers of small vessel disease, atrophy, white matter integrity and cerebrovascular reactivity (CVR) were quantified. Logistic regression was used to compute areas under the receiver operating characteristic curve (AUC) to assess biomarker discriminative performance of ascertaining a diagnosis of CAA. Associations between plasma biomarkers, cognition and neuroimaging biomarkers were evaluated with generalized linear models. RESULTS: 45 participants with CAA and 47 controls were eligible. With both methods, the Aβ42/40 ratio was reduced in CAA compared to controls. Furthermore, those with CAA had elevated p-tau181 and NfL. A combination of Aβ42/40 (Simoa), p-tau181, and NfL resulted in an AUC of 0.90. Reduced Aβ42/40 was associated with poorer speed of processing. Increasing NfL was associated with reduced Montreal Cognitive Assessment Scores, lower CVR and increasing CAA severity. CONCLUSIONS: This study identified differences in plasma Aβ42/40, p-tau181 and NfL in CAA compared and provides evidence that a panel of these biomarkers can achieve excellent diagnostic discriminability. This study also demonstrates that a marker of cerebral amyloidosis (Aβ42/40) is associated with speed of processing difficulties in those with CAA, while NfL was associated with global cognition, CAA severity and CVR. Overall, plasma biomarkers might, in future, help improve the evaluation and detection of CAA.
Description
Keywords
Cerebral Amyloid Angiopathy, Hemorrhagic Stroke, Plasma Biomarkers, Cerebral Small Vessel Disease
Citation
Muir, R. T. (2024). Characterizing plasma biomarkers of cerebral amyloid angiopathy (Master's thesis, University of Calgary, Calgary, Canada). Retrieved from https://prism.ucalgary.ca.